NCT04666610: An ongoing trial by UCB Biopharma SRL
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04666610 |
|---|---|
| Title | A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 29, 2021 |
| Completion date | Feb. 25, 2027 |
| Required reporting date | Feb. 25, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 27, 2025 |
| Days late | None |